Clearside Biomedical announced that their proprietary formulation of triamcinolone acetonide (CLS - TA) improved vision in patients
with macular edema from noninfectious uveitis.
Clearside Biomedical announced that a special formulation of triamcinolone acetonide showed good outcomes in patients
with macular edema associated with non-infectious uveitis.
Not exact matches
About 750,000 Americans
with diabetic retinopathy have diabetic
macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead.
This increase was found in the Chinese American study participants
with Type II diabetes who had cataracts or
macular edema resulting in visual impairments.
The study included 103 adults
with type 2 diabetes, seen at a public health clinic, who were considered at high risk for
macular edema.
This
macular edema is one of the most serious vision - threatening changes in the eyes of people
with diabetes.
In their study, Dr Cuadros and coauthors sought to determine whether hard exudates in clinic photographs are an accurate indicator of clinically significant
macular edema in patients
with diabetes.
Optometrists and ophthalmologists,
with specialized training and instruments, can diagnose
macular edema.
If left untreated, about a quarter of people
with diabetes eventually lose some of their vision from diabetic
macular edema — a condition in which leaking blood vessels cause swelling in the center of the retina.
«These results indicate a treatment breakthrough for saving the vision of people
with diabetic
macular edema,» said Neil M. Bressler, M.D., chair of the DRCR.net and chief of the Retina Division at the Wilmer Eye Institute, Johns Hopkins University.
Participants, who were on average in their early 60s, were diagnosed
with type 1 or 2 diabetes and
macular edema.
The DRCR.net was founded in 2002 through a cooperative agreement
with the National Institutes of Health to form a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic
macular edema and associated conditions.
«This comparative - effectiveness study demonstrated that a new treatment can protect and, in many cases, improve the vision of people
with diabetic
macular edema,» said NEI Director Paul A. Sieving, M.D., Ph.D..